Viridian Therapeutics is a biopharmaceutical company. Co. has built relevant capabilities in monoclonal antibody discovery and engineering, biologics manufacturing, and nonclinical and clinical development for thyroid eye disease (TED) and other undisclosed target indications in rare and autoimmune diseases. Co. is developing three product candidates, VRDN-001, VRDN-002, and VRDN-003, that are being developed for intravenous or subcutaneous administration to treat patients who suffer from TED. Co.'s primary program, VRDN-001, is a humanized monoclonal antibody targeting insulin-like growth factor 1 receptor intravenously administered for the treatment for TED. The VRDN average annual return since 2014 is shown above.
The Average Annual Return on the VRDN average annual return since 2014 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether VRDN average annual return since 2014 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the VRDN average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|